Newshero

RECENT NEWS

For Media Inquiries

Alisa Santiesteban, Director of Marketing & Communications
970-926-1277 / Alisa@CanDo-MS.org

Media Kit


Lokai Launches Multiple Sclerosis Teal Bracelet

March 4th, 2019

Lokai, the socially responsible brand representing the importance of finding balance along life’s journey, announced a new teal bracelet in partnership with Can Do Multiple Sclerosis (Can Do MS).

Continue Reading
JUMPSTART® Program Coming to Fargo, ND, on March 30

February 25th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, March 30, in Fargo, ND. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to Oakland, CA, on March 16

February 11th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, March 16, in Oakland, CA. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to West Hartford, CT, on March 9

February 4th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, March 9, 2019, in West Hartford, CT. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to Long Beach, CA, on March 2

January 30th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, March 2, 2019, in Long Beach, CA. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to Chicago, IL, on February 9

January 10th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, February 9, 2019, in Chicago, IL. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to Dallas, TX, on February 9

January 7th, 2019

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, February 9, in Dallas, TX. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
JUMPSTART® Program Coming to Houston, TX, on January 26

December 20th, 2018

Can Do Multiple Sclerosis is holding a free, one-day JUMPSTART® Program on Saturday, January 26, in Houston, TX. This educational and interactive program enables people with MS and their support partners to learn the knowledge, skills, and tools to adopt healthy lifestyle behaviors and actively co-manage their MS.

Continue Reading
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis

December 17th, 2018

BrainStorm Cell Therapeutics Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis.

Continue Reading
​Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

December 17th, 2018

Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated profile. The data encompassed in the regulatory package underscore diroximel fumarate’s potential to be a meaningful, new treatment option for the MS community.

Continue Reading